A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients

Trial Profile

A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Apr 2018

At a glance

  • Drugs CDX-3379 (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Pharmacodynamics
  • Sponsors Celldex Therapeutics Inc; Kolltan Pharmaceuticals
  • Most Recent Events

    • 20 Apr 2018 According to a Celldex Therapeutics Inc media release, the data from this study has been presented at the American Association for Cancer Research (AACR) Annual Meeting 2018.
    • 20 Apr 2018 Primary endpoint has been met. (Change in pErbB3 levels in tumor tissue), according to a Celldex Therapeutics Inc media release.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top